Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors

Fig. 1

Treatment response to anti–PD-1 antibody in cohort 1. (Upper) Pie charts demonstrating the response in primary lung cancer and paired brain metastases. (Lower) The treatment response along with clinicodemographic characteristics of individual patients in cohort 1. Each patient received either nivolumab (N) or pembrolizumab (P) for the specified number of cycles. Each tile in this figure denotes the treatment response: red for progressive disease, blue for stable disease, and green for a partial response. Abbreviations: PD, progressive disease; PR, partial response; SD, stable disease; ID, identification number; P, pembrolizumab; N, nivolumab; PD-L1, programmed cell death ligand-1; PD-1, programmed cell death-1; M, male; F, female; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NS, never smoked; ES, ex-smoker; CS, current smoker; ADC, adenocarcinoma; SAR, pulmonary sarcomatoid carcinoma; SCL, small-cell lung cancer; SQC, squamous cell carcinoma, Erlo., erlotinib; Gefi., gefitinib; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor. a: Exon 20 insertion. b: Exon 19 deletion. c: L858R mutation

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us